MAPK-IN-1

• UNSPSC Description:

  MAPK-IN-1 (Compound 2) is a MAPK signaling pathway inhibitor. MAPK-IN-1 exhibits AChE inhibitory activity with an IC50 of 23.84 μM. MAPK-IN-1 shows anti-neuroinflammatory and neuroprotective activity and can be used for Alzheimer's disease research[1].

• Target Antigen:

  Cholinesterase (ChE); ERK; JNK; p38 MAPK; Toll-like Receptor (TLR)

• Type:

  Reference compound

• Related Pathways:

  Immunology/Inflammation;MAPK/ERK Pathway;Neuronal Signaling;Stem Cell/Wnt

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology; Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/mapk-in-1.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C1CCC(C2=C(C3=C(C(C2=O)=O)[C@@H](C)CO3)C=C4)=C4C1(C)C

• Molecular Weight:

  310.34

• References & Citations:

  [1]Wu JS, et al. The oxygenated products of cryptotanshinone by biotransformation with Cunninghamella elegans exerting anti-neuroinflammatory effects by inhibiting TLR 4-mediated MAPK signaling pathway. Bioorg Chem. 2020 Nov;104:104246.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2470587-69-8